Home » Stocks » ICAD

iCAD, Inc. (ICAD)

Stock Price: $15.16 USD 0.13 (0.86%)
Updated Jan 22, 2021 4:00 PM EST - Market closed
Market Cap 348.58M
Revenue (ttm) 28.63M
Net Income (ttm) -19.36M
Shares Out 23.17M
EPS (ttm) -0.91
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day January 22
Last Price $15.16
Previous Close $15.03
Change ($) 0.13
Change (%) 0.86%
Day's Open 15.06
Day's Range 14.10 - 15.25
Day's Volume 202,890
52-Week Range 6.63 - 15.25

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
GlobeNewsWire - 5 days ago

NASHUA, N.H., Jan. 19, 2021 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced that ...

GlobeNewsWire - 2 weeks ago

New ProFound AI risk software, offering a 2-year projected risk score to be featured New ProFound AI risk software, offering a 2-year projected risk score to be featured

GlobeNewsWire - 3 weeks ago

International Multi-Center Study to Commence January 2021

GlobeNewsWire - 1 month ago

Agreement Positions Both Companies for Growth; Leading-edge AI Technology to be Installed Across Largest Independent Provider of Mammography and Breast Health Services' Network Agreement Posit...

GlobeNewsWire - 1 month ago

Groundbreaking ProFound AI Risk Helps Transform Breast Cancer Screening from an Age-Based Paradigm to Risk-Adapted Precision Screening, Individualized for Each Woman Groundbreaking ProFound AI...

GlobeNewsWire - 1 month ago

Growing Body of Evidence Supports Xoft Platform Across Multiple Cancer Types Growing Body of Evidence Supports Xoft Platform Across Multiple Cancer Types

GlobeNewsWire - 2 months ago

Significant Percentage of Licenses Sold to Facilities with GE, Siemens, and Sites with Multiple Vendors Including Hologic and Fuji

Seeking Alpha - 2 months ago

iCAD, Inc. (ICAD) CEO Michael Klein on Q3 2020 Results - Earnings Call Transcript

GlobeNewsWire - 2 months ago

Achieved Sequential Revenue Growth of 28% in Third Quarter of 2020, Driven by Detection Product and Therapy Product Revenue Growth of 44% and 251%, Respectively

GlobeNewsWire - 2 months ago

NASHUA, N.H., Oct. 29, 2020 (GLOBE NEWSWIRE) --  iCAD , Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced tha...

GlobeNewsWire - 3 months ago

iCAD Showcasing Expanded Xoft Platform Including Single-Fraction IORT Solution for Brain and Early-Stage Breast Cancer Tumors iCAD Showcasing Expanded Xoft Platform Including Single-Fraction I...

GlobeNewsWire - 3 months ago

Contract with market-leading enterprise imaging provider expands access to ProFound AI for hospitals and imaging centers across North America Contract with market-leading enterprise imaging pr...

GlobeNewsWire - 3 months ago

New, Encouraging Results and Overall Patient Survival Numbers to be Presented at European Congress of Neurosurgery New, Encouraging Results and Overall Patient Survival Numbers to be Presented...

GlobeNewsWire - 3 months ago

Webinar Taking Place on Wednesday, October 21st @ 10amET Webinar Taking Place on Wednesday, October 21st @ 10amET

GlobeNewsWire - 4 months ago

IORT reimbursement unchanged; payment values for alternative, longer courses of radiation therapy reduced IORT reimbursement unchanged; payment values for alternative, longer courses of radiat...

GlobeNewsWire - 4 months ago

NASHUA, N.H., Sept. 18, 2020 (GLOBE NEWSWIRE) -- iCAD , Inc . (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today provided ...

GlobeNewsWire - 4 months ago

Leading experts in multiple disciplines to share best practices on leveraging AI in clinical settings Leading experts in multiple disciplines to share best practices on leveraging AI in clinic...

GlobeNewsWire - 4 months ago

NASHUA, N.H., Aug. 27, 2020 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced t...

GlobeNewsWire - 5 months ago

NASHUA, N.H., Aug. 10, 2020 (GLOBE NEWSWIRE) -- iCAD , Inc . (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced ...

Seeking Alpha - 5 months ago

iCAD, Inc. (ICAD) CEO Michael Klein on Q2 2020 Results - Earnings Call Transcript

GlobeNewsWire - 5 months ago

Launched ProFound AI™ Risk Offering After Receiving CE Mark in Europe

GlobeNewsWire - 5 months ago

NASHUA, N.H., July 28, 2020 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced t...

GlobeNewsWire - 6 months ago

First and only commercially available clinical decision support tool provides accurate  two-year breast cancer risk estimation personalized for each woman

GlobeNewsWire - 6 months ago

Leading-edge artificial intelligence (AI) software allows patients to receive “real time” essential breast screening amidst pandemic Leading-edge artificial intelligence (AI) software allows p...

GlobeNewsWire - 6 months ago

NASHUA, N.H., June 29, 2020 (GLOBE NEWSWIRE) -- iCAD , Inc . (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced ...

GlobeNewsWire - 9 months ago

NASHUA, N.H., April 23, 2020 (GLOBE NEWSWIRE) -- iCAD, Inc. (“iCAD”) (Nasdaq: ICAD) today announced it has entered into definitive agreements with several institutional investors for the pur...

GlobeNewsWire - 9 months ago

Educational awareness forum to feature leading experts in discussions on risk adaptive tools and pragmatic solutions to enhance patient care during COVID-19 pandemic

GlobeNewsWire - 9 months ago

NASHUA, N.H., March 31, 2020 (GLOBE NEWSWIRE) -- iCAD , Inc . (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced...

Seeking Alpha - 10 months ago

iCAD, Inc. (ICAD) CEO Michael Klein on Q4 2019 Results - Earnings Call Transcript

GlobeNewsWire - 11 months ago

iCAD’s cancer detection and therapy technologies to be exhibited together for the first time in the Middle East, including the world’s first commercial deep-learning digital breast tomosynthes...

GlobeNewsWire - 1 year ago

World’s first and largest open AI Marketplace expands access to ProFound AI for U.S. radiologists, 80 percent of whom use Nuance’s radiology reporting system World’s first and largest open AI ...

GlobeNewsWire - 1 year ago

Company Unveils New Initiative, ProFound AI Powered by Panorama, which will Enable Breast Imaging Intelligence Technology to Correlate Findings Over Time Company Unveils New Initiative, ProFou...

Seeking Alpha - 1 year ago

ICAD, Inc. (ICAD) CEO Michael Klein on Q3 2019 Results - Earnings Call Transcript

GlobeNewsWire - 1 year ago

Continued strong momentum for ProFound AI™ iCAD’s proprietary cancer detection AI technology

GlobeNewsWire - 1 year ago

iCAD to Showcase Entire ProFound AI Platform, including its Solutions for 2D Mammography and Digital Breast Tomosynthesis in Paris at Medical Conference iCAD to Showcase Entire ProFound AI Pla...

GlobeNewsWire - 1 year ago

iCAD présentera la plateforme complète ProFound AI, comprenant ses solutions pour la mammographie 2D et pour la tomosynthèse mammaire numérique, lors du Congrès de Radiologie à Paris iCAD prés...

GlobeNewsWire - 1 year ago

Company to exhibit ProFound AI for 2D and 3D Mammography in Europe Company to exhibit ProFound AI for 2D and 3D Mammography in Europe

GlobeNewsWire - 1 year ago

Enhanced x-ray source technology and full suite of Xoft eBx applicators to be showcased, including those for emerging applications in prostate, brain, and rectal cancers Enhanced x-ray source ...

GlobeNewsWire - 1 year ago

First and Only FDA-Cleared Digital Breast Tomosynthesis Software with Artificial Intelligence Clinically Proven to Enhance Breast Cancer Screening, Reduce False Positives and Slash Reading Tim...

GlobeNewsWire - 1 year ago

First and Only FDA-Cleared Artificial Intelligence Solution Supporting Breast Cancer Detection in 3D Tomosynthesis Recognized by Annual Awards Program First and Only FDA-Cleared Artificial Int...

Seeking Alpha - 1 year ago

iCAD's (ICAD) CEO Michael Klein on Q2 2019 Results - Earnings Call Transcript

Seeking Alpha - 1 year ago

iCAD's (ICAD) CEO Michael Klein on Q1 2019 Results - Earnings Call Transcript

Seeking Alpha - 1 year ago

iCAD, Inc. (ICAD) CEO Michael Klein on Q4 2018 Results - Earnings Call Transcript

About ICAD

iCAD provides image analysis, workflow solutions, and radiation therapy for the treatment of cancer in the United States. It operates through two segments, Cancer Detection and Cancer Therapy. The company offers PowerLook platform, which hosts the AI algorithm solutions and manages the communications between imaging acquisition systems, and image storage and review systems; SecondLook, a machine learning-based cancer detection algorithm that analyzes 2D full-field digital mammography images to identify and mark suspicious masses and calcificati... [Read more...]

Industry
Health Information Services
IPO Date
Dec 3, 1986
CEO
Michael S. Klein
Employees
135
Stock Exchange
NASDAQ
Ticker Symbol
ICAD
Full Company Profile

Financial Performance

In 2019, iCAD, Inc.'s revenue was $31.34 million, an increase of 22.32% compared to the previous year's $25.62 million. Losses were -$13.55 million, 50.3% more than in 2018.

Financial Statements

Analyst Forecasts

According to 6 analysts, the average rating for iCAD, Inc. stock is "Buy." The 12-month stock price forecast is 15.92, which is an increase of 5.01% from the latest price.

Price Target
$15.92
(5.01% upside)
Analyst Consensus: Buy